Analysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (NASDAQ: GLMD) and Horizon Pharma Inc (NASDAQ: HZNP)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Galmed Pharmaceuticals (NASDAQ: GLMD) and Horizon Pharma Inc (NASDAQ: HZNP) with bullish sentiments.

Galmed Pharmaceuticals (NASDAQ: GLMD)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Galmed Pharmaceuticals (NASDAQ: GLMD) today and set a price target of $14. The company’s shares opened today at $5.36.

McCarthy said:

“Galmed reported 1Q18 with a net loss of $2.5M and ended the period with $15.5M in cash. Operating expenses were lower this quarter as the ARREST study in NASH is nearing completion. The data is expected in June and in our view is a “pivotal” event for the company..”

According to TipRanks.com, McCarthy is a 2-star analyst with an average return of 0.5% and a 38.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.

Galmed Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $19.

See today’s analyst top recommended stocks >>

Horizon Pharma Inc (NASDAQ: HZNP)

In a report released today, Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Horizon Pharma Inc (NASDAQ: HZNP), with a price target of $17. The company’s shares opened today at $13.48.

Chen said:

“Positives from the quarter that support our thesis: 1) orphan and rheumatology sales of $172.2MM, up 11%, 77% of total sales; 2) Krystexxa sales of $46.7MM, up 48%; HZNP increased its 2018 sales growth guidance to 65%+; 3) announced new operating structure aligned with long-term strategy of realigning business into two operating segments: strategic growth business, orphan and rheumatology and primary care; 4) Teprotumumab Phase 3 clinical trial now 50% enrolled, ahead of expectations; and 5) as of 3/31/18, cash and cash equivalents totaled $674.3MM, net debt was $1.3B, and net debt to LTM adjusted EBITDA leverage ratio was 3.6x.”

According to TipRanks.com, Chen ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.3% and a 37.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.

Currently, the analyst consensus on Horizon Pharma Inc is Strong Buy and the average price target is $20.20, representing a 49.9% upside.

In a report issued on May 7, Mizuho Securities also reiterated a Buy rating on the stock with a $18 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.